Insider Trading Activity For Blueprint Medicines Corporation (NASDAQ:BPMC)
Anthony L Boral , Insider of Blueprint Medicines Corporation (NASDAQ:BPMC) reportedly Sold 5,000 shares of the company’s stock at an average price of 48.6 for a total transaction amount of $243,000.00 SEC Form
Insider Trading History For Blueprint Medicines Corporation (NASDAQ:BPMC)
Analyst Ratings For Blueprint Medicines Corporation (NASDAQ:BPMC)
These are 7 Buy Ratings .
The current consensus rating for Blueprint Medicines Corporation (NASDAQ:BPMC) is Buy (Score: 3.00) with a consensus target price of $48.46 , a potential (5.09% upside)
Analyst Ratings History For Blueprint Medicines Corporation (NASDAQ:BPMC)
- On 3/9/2016 J P Morgan Chase & Co Lower Price Target of rating Market Outperform with a price target of $54.00 to $37.00
- On 5/27/2016 Raymond James Financial, Inc. Initiated Coverage of rating Outperform with a price target of $23.00
- On 2/15/2017 Morgan Stanley Initiated Coverage of rating Overweight with a price target of $45.00
- On 3/13/2017 Goldman Sachs Group, Inc. (The) Upgraded rating Neutral to Buy with a price target of $52.00
- On 3/22/2017 JMP Securities Initiated Coverage of rating Outperform with a price target of $37.00 to $46.00
- On 5/4/2017 Jefferies Group LLC Boost Price Target of rating Buy with a price target of $42.00 to $52.00
- On 6/6/2017 Wedbush Reiterated Rating Outperform with a price target of $55.00
Recent Trading Activity for Blueprint Medicines Corporation (NASDAQ:BPMC)
Shares of Blueprint Medicines Corporation closed the previous trading session at 46.11 down -0.85 -1.81% with 299,743 shares trading hands.